Inhibikase Therapeutics, Inc. (IKT)

Every figure this model derived for IKT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 159,018,847 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 162,343,915 AssetsCurrent 2026-06-30
current liabilities 10,260,026 LiabilitiesCurrent 2026-06-30
equity 153,328,586 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2023-12-31
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IKT on one particular measure came for.

RatioValue
current ratio15.82
current ratio reported15.82
deferred revenue growth-100.0
dilution pct315.0
growth cv2.82
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about IKT's figures. Written by the derivation as it ran, not added afterwards.